The US regulator has accepted for Priority Review a bid to broaden the label for the antibody Dupixent (dupilumab) in moderate-to-severe atopic dermatitis. 10 February 2022
Dermavant Sciences, an immuno-dermatology-focused subsidiary of Switzerland-based Roivant Sciences, has released positive data from a patient satisfaction quest 17 January 2022
Chicagoan biotech AbbVie (NYSE: ABBV) says its JAK inhibitor Rinvoq (upadacitinib) will likely generate half a billion dollars less in annual revenues by 2025, 13 January 2022
German pharmaceutical firm Boehringer Ingelheim has published new data from the pivotal Phase II Effisayil trial in the New England Journal of Medicine. 23 December 2021
Topical dermatology specialist DermBiont has raised $28 million in a series A financing, at the same time as acquiring clinical-stage biotech Chromaderm. 21 December 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.